Lithium

Earlier this year, Alzamend Neuro announced the completion of a device designed by Tesla Dynamic Coils, to monitor lithium levels in the brain, which will help researchers identify therapeutic target doses for a range of neuropsychiatric conditions.

NEW YORK — Although guidelines have historically advised against lithium use while breastfeeding, there is a “clear need” for more research and monitoring guidance for patients who would like to breastfeed while on lithium.

NEW YORK — Lithium exposure in drinking water was associated with potentially detrimental effects on human health, including increased risk for autism spectrum disorder and schizophrenia spectrum disorder, according to researchers.

A potential next-generation lithium treatment is set to be tested in major depressive disorder after the FDA issued a “study may proceed” letter for a phase 2a trial of AL001 by Alzamend Neuro.

A potential new lithium treatment for bipolar disorder, designed to avoid toxicities currently associated with the substance, is set to undergo a phase 2 study.

Use of lithium vs. valproate as a prophylactic treatment may be associated with adverse kidney outcomes, including AKI, according to recently published research.

Topline data from a phase 2a, multiple ascending dose study identified a maximum tolerated dose for development of AL001, an investigational lithium-delivery system, according to a press release from manufacturer Alzamend Neuro.

A study of more than 50,000 children born over a 14-year period in Denmark found that children born to mothers who were exposed to higher levels of lithium in their drinking water were moderately more likely to develop autism.

Alzamend Neuro Inc. has announced the launch of a phase 2A trial for its AL001 treatment for mild to moderate Alzheimer’s dementia.

Adding lithium to usual care for veterans with major depression or bipolar disorders did not reduce incidence of suicide-related events, according to results of a randomized clinical trial published in JAMA Psychiatry.